Chiesi to license Phase II AD compound to newco

Chiesi Farmaceutici S.p.A. (Parma, Italy) said it signed a letter of intent with CereSpir Inc. (New York, N.Y.) to grant the newco exclusive, worldwide rights to develop and commercialize CHF 5074, a ...